A new treatment for advanced prostate cancer that has stopped responding to abiraterone.
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
['FUNDING_SBIR_2'] · SYNTRIX BIOSYSTEMS, INC. · NIH-11114019
This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SYNTRIX BIOSYSTEMS, INC. (nih funded) |
| Locations | 1 site (AUBURN, UNITED STATES) |
| Trial ID | NIH-11114019 on ClinicalTrials.gov |
What this research studies
Prostate cancer is a serious concern for many men, especially when it spreads and becomes resistant to standard treatments like abiraterone. When this happens, current options are limited, and only a small percentage of men respond to further treatments like enzalutamide alone. This new approach combines enzalutamide with an investigational medicine called SX-682, which targets specific signals (CXCR1/2) that help prostate cancer grow and resist treatment. By blocking these signals, the hope is to make enzalutamide more effective and offer a new way to fight advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates are men with metastatic castration-resistant prostate cancer whose disease has progressed despite prior treatment with abiraterone.
Not a fit: Patients whose prostate cancer is still responding to abiraterone or who have not yet developed metastatic castration-resistant disease would not be the focus of this particular approach.
Why it matters
Potential benefit: If successful, this new combination therapy could offer a much-needed treatment option for men with advanced prostate cancer that no longer responds to abiraterone, potentially extending their lives.
How similar studies have performed: While the specific combination is new, the targets (CXCR1/2) have been identified as important in prostate cancer resistance, suggesting a strong scientific basis for this novel approach.
Where this research is happening
AUBURN, UNITED STATES
- SYNTRIX BIOSYSTEMS, INC. — AUBURN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHULER, AARON D — SYNTRIX BIOSYSTEMS, INC.
- Study coordinator: SCHULER, AARON D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.